A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Stereotypical Prolonged Seizures
About this trial
This is an interventional treatment trial for Stereotypical Prolonged Seizures focused on measuring Stereotypical prolonged seizures, Phase 3, Staccato alprazolam
Eligibility Criteria
Inclusion Criteria:
- Participant must be ≥12 years of age at the Baseline/Randomization Visit
- Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures
Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following:
- Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes
- Episodes of a focal seizure with a minimum duration of 3 minutes
- Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes
- Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit
- Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder
- Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit
Male and female participants:
- A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after IMP administration and refrain from donating sperm during this period
- A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration
- Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The ICF or a specific assent form, where required, will be signed and dated by minors
- The participant's study caregiver(s) must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the iPMP
Exclusion Criteria:
- Participant has a current history of alcohol or drug use disorder, as defined in the Diagnostic and Statistical Manual of Mental Disorders 5, within the previous 1 year
- Participant has a known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) as stated in this protocol or to albuterol (or similar bronchospasm rescue medication if needed to meet country-specific requirements)
- Participant has a diagnosis of atrial fibrillation or mitral stenosis
- Participant has a history of convulsive (generalized tonic-clonic) status epilepticus in the 8 weeks prior to the Screening Visit
- Participant has a history or presence of known nonepileptic seizures which cannot be distinguished from qualifying epileptic seizures
- Participant has a clinically significant known airway hypersensitivity (eg, bronchospasm to known allergens, such as pollen, animals, or food) and/or acute respiratory signs/symptoms (eg, shortness of breath, wheezing on lung auscultation)
- Participant has a clinically significant chronic pulmonary disorder other than mild asthma (eg, chronic obstructive pulmonary disease, restrictive lung diseases [including idiopathic pulmonary fibrosis]) and/or recent history or presence of hemoptysis or pneumothorax
- Participant has had a positive antigen test for acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced moderate to severe signs/symptoms of respiratory distress necessitating hospitalization or outpatient treatment such as ambulatory oxygen, extensive treatment with inhaler medications, and/or oral medications for a duration of 4 weeks or more, unless full resolution occurred at least 6 months prior to Screening
- Participant has experienced a upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months before the Screening Visit
- Participant has a history or presence of acute narrow-angle glaucoma
- Participant has a condition for which oral alprazolam is contraindicated (eg, myasthenia gravis, severe respiratory insufficiency, and sleep apnea syndrome)
- Participant has a history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope
- Chronic use of benzodiazepines for more than 3 days within a period of 7 days will be allowed for approximately 30 % of study participants
- Participant is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone
- Participant is taking any opioids (eg, fentanyl, oxycodone, morphine) or sedative hypnotics on a chronic basis
- Participant is taking nonselective beta blockers on a chronic basis
- Participant is taking pharmacotherapy for an active major psychiatric disorder where major changes in regimen are needed or anticipated during the study
- Participant has been treated with vagal nerve stimulation (VNS) for less than 6 months or VNS settings have changed within 30 days before the Screening Visit
- Participant has a clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
- Participant has an oxygen saturation <95 % (or less than normal in regions of altitude >2500 meters) for greater than 30 seconds during the Screening Visit. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
- Participant has >2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total bilirubin for liver impairment)
- Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis
- Participant has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc interval >470 msec (females), or QTc interval >480 msec (participants with bundle branch block), PR interval ≥220 msec, or any other clinically significant electrocardiogram (ECG) abnormality according to the Investigator i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF). It is either machine-read or manually over-read
- Participant has a positive urine screen for drugs of abuse at the Screening Visit
- Participant has a blood pressure (BP) or heart rate (HR) outside the following range after 5 minutes rest: systolic BP: 90 mmHg to 150 mmHg; diastolic BP: 4 0mmHg to 95 mmHg; HR: 50 bpm to 100 bpm. In case of an out-of-range result, 1 repeat will be allowed. If the readings are out of range again, the study participant will be excluded
Sites / Locations
- Ep0162 50506Recruiting
- Ep0162 50494Recruiting
- Ep0162 50118Recruiting
- Ep0162 50505Recruiting
- Ep0162 50492Recruiting
- Ep0162 50367Recruiting
- Ep0162 50088Recruiting
- Ep0162 50515Recruiting
- Ep0162 50508Recruiting
- Ep0162 50342Recruiting
- Ep0162 50199Recruiting
- Ep0162 50509Recruiting
- Ep0162 50308Recruiting
- Ep0162 50323Recruiting
- Ep0162 50512Recruiting
- Ep0162 50493Recruiting
- Ep0162 50375Recruiting
- Ep0162 50504Recruiting
- Ep0162 50395Recruiting
- Ep0162 50517Recruiting
- Ep0162 50093Recruiting
- Ep0162 50488Recruiting
- Ep0162 50047Recruiting
- Ep0162 50110Recruiting
- Ep0162 50507Recruiting
- Ep0162 50499
- Ep0162 50299Recruiting
- Ep0162 50497Recruiting
- Ep0162 50298Recruiting
- Ep0162 50490Recruiting
- Ep0162 50518Recruiting
- Ep0162 50034Recruiting
- Ep0162 50514Recruiting
- Ep0162 50487Recruiting
- Ep0162 50371Recruiting
- Ep0162 50528Recruiting
- Ep0162 50510
- Ep0162 50096Recruiting
- Ep0162 50364Recruiting
- Ep0162 50089Recruiting
- Ep0162 50511Recruiting
- Ep0162 50491Recruiting
- Ep0162 50513Recruiting
- Ep0162 50103Recruiting
- Ep0162 50525Recruiting
- Ep0162 50496
- Ep0162 50473Recruiting
- Ep0162 30016Recruiting
- Ep0162 30030Recruiting
- Ep0162 30027Recruiting
- Ep0162 30031Recruiting
- Ep0162 40650Recruiting
- Ep0162 40708Recruiting
- Ep0162 40665Recruiting
- Ep0162 40709Recruiting
- Ep0162 40651Recruiting
- Ep0162 20128Recruiting
- Ep0162 20246Recruiting
- Ep0162 20268Recruiting
- Ep0162 20299Recruiting
- Ep0162 20261Recruiting
- Ep0162 20133Recruiting
- Ep0162 20137Recruiting
- Ep0162 20250Recruiting
- Ep0162 20124Recruiting
- Ep0162 20260Recruiting
- Ep0162 20264Recruiting
- Ep0162 20269Recruiting
- Ep0162 20300Recruiting
- Ep0162 20258Recruiting
- Ep0162 20253Recruiting
- Ep0162 20267Recruiting
- Ep0162 20123Recruiting
- Ep0162 20289Recruiting
- Ep0162 20119Recruiting
- Ep0162 20257Recruiting
- Ep0162 20025Recruiting
- Ep0162 20252Recruiting
- Ep0162 20255Recruiting
- Ep0162 20262Recruiting
- Ep0162 20251Recruiting
- Ep0162 40670Recruiting
- Ep0162 40672Recruiting
- Ep0162 40714Recruiting
- Ep0162 40063Recruiting
- Ep0162 40671Recruiting
- Ep0162 40681Recruiting
- Ep0162 40688Recruiting
- Ep0162 40680Recruiting
- Ep0162 40019Recruiting
- Ep0162 40682Recruiting
- Ep0162 40201Recruiting
- Ep0162 40199Recruiting
- Ep0162 40577
- Ep0162 40683Recruiting
- Ep0162 40685Recruiting
- Ep0162 40023Recruiting
- Ep0162 40645Recruiting
- Ep0162 40689Recruiting
- Ep0162 40529Recruiting
- Ep0162 40666Recruiting
- Ep0162 40673Recruiting
- Ep0162 40704Recruiting
- Ep0162 40653Recruiting
- Ep0162 40690Recruiting
- Ep0162 40674Recruiting
- Ep0162 40144Recruiting
- Ep0162 40477Recruiting
- Ep0162 40257Recruiting
- Ep0162 40675Recruiting
- Ep0162 20248Recruiting
- Ep0162 20237Recruiting
- Ep0162 20249Recruiting
- Ep0162 20236Recruiting
- Ep0162 20239Recruiting
- Ep0162 20143Recruiting
- Ep0162 20243Recruiting
- Ep0162 20235Recruiting
- Ep0162 20238Recruiting
- Ep0162 20241Recruiting
- Ep0162 20302Recruiting
- Ep0162 20316Recruiting
- Ep0162 20297Recruiting
- Ep0162 20240Recruiting
- Ep0162 20242Recruiting
- Ep0162 20266Recruiting
- Ep0162 20244Recruiting
- Ep0162 40707Recruiting
- Ep0162 40677Recruiting
- Ep0162 40219Recruiting
- Ep0162 40502Recruiting
- Ep0162 40676Recruiting
- Ep0162 40091Recruiting
- Ep0162 40153Recruiting
- Ep0162 40678Recruiting
- Ep0162 40160Recruiting
- Ep0162 40540Recruiting
- Ep0162 40352Recruiting
- Ep0162 40668Recruiting
- Ep0162 40453Recruiting
- Ep0162 40230Recruiting
- Ep0162 40667Recruiting
- Ep0162 40686Recruiting
- Ep0162 40300Recruiting
- Ep0162 40163Recruiting
- Ep0162 40108Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Staccato alprazolam Arm
Placebo Arm
Participants randomized to this arm will receive a single dose of Staccato alprazolam by inhalation.
Participants randomized to this arm will receive a single dose of placebo by inhalation.